Service

 

Our (e)Books and (e)Journals

IOS Press serves the information needs of scientific and medical communities worldwide. See what's new and browse our books and journals to learn more.

Service

 

Estrogen Replacement May Protect Against Alzheimer’s Disease in Women

September 1, 2020 - Amsterdam, NL – Alzheimer's disease (AD) is the most common neurodegenerative disease and the leading cause of dementia. It affects more women than men. A new study published in the Journal of Alzheimer’s Disease indicates that factors such as age, reproductive stage, hormone levels, and the interplay with other risk factors should be considered in women and proposes a role for early menopausal estrogen replacement to protect against the development of AD.

September 1, 2020

Stress Overload and Pain Common Among Patients with Traumatic Brain Injury

August 18, 2020 - Amsterdam, NL – Traumatic brain injury (TBI) is a leading cause of death and disability. Post-injury distress is common, with many individuals experiencing chronic anxiety and depressive symptoms as well as chronic pain. In this collection of articles in the journal NeuroRehabilitation, experts report on findings that shed light on the relationship between stress and pain following a TBI and implications for rehabilitation.

August 18, 2020

Body Weight Has Surprising, Alarming Impact on Brain Function

August 5, 2020 - Amsterdam, NL and Costa Mesa, CA, USA – As a person's weight goes up, all regions of the brain go down in activity and blood flow, according to a new brain imaging study in the Journal of Alzheimer's Disease. One of the largest studies linking obesity with brain dysfunction, scientists analyzed over 35,000 functional neuroimaging scans using single-photon emission computerized tomography from more than 17,000 individuals to measure blood flow and brain activity.

August 5, 2020

The Outlook Is Encouraging: Researchers Evaluate a Pipeline of Clinical Trials Targeting Parkinson’s Disease

August 3, 2020 - Amsterdam, NL – A review of currently registered clinical trials of agents targeting Parkinson's disease (PD) reveals that there is a broad pipeline of both symptomatic and potentially disease-modifying therapies currently being evaluated. Investigators report that the outlook for patients is encouraging, given the wide range of therapeutics being clinically tested. They emphasize the importance of engaging the Parkinson's community in the research. Their analysis and results are published in the Journal of Parkinson's Disease.

August 3, 2020